Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation

Fig. 3

Prevention of pulmonary hypertension development in the BGF-treated groups. A Schematic diagram of the experimental design. BALB/c mice were treated with drug combinations or control vehicle on Day 14 after elastase treatment, hemodynamically analyzed, and sacrificed on Day 28. Lung and heart tissues were collected for further analysis. B Echocardiographic pulmonary artery acceleration time (PAAT) measurement results on Day 25. n = 3–13 mice per group. C Right ventricular systolic pressure (RVSP) measurement results via right heart catheterization just prior to termination on Day 28. n = 3–10 mice per group. D Right ventricular hypertrophy index (Fulton Index) measurement. n = 3–13 mice per group. The data are presented as the mean ± S.E.M. (standard error of mean). One-way ANOVA with Tukey’s post-hoc test was used for Figs. 3B-D. *, p < 0.05 compared with the PBS/Vehicle group, #, p < 0.05 compared with the PBS/Elastase group for (B)

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us